Off-target binding can be a significant hurdle in the development of antibody-based therapies, contributing to both drug attrition and adverse events in patients. Recent analysis of a panel of preclinical and clinical stage antibodies identified a surprisingly high off-target rate across the industry, with up to one-third of antibody drugs displaying off-target binding. Limitations of conventional screening methods, mainly tissue cross-reactivity (TCR) studies, have contributed to polyspecificity going undetected. So, what are the alternatives?
Join our webinar to learn about a better approach to specificity profiling using new, innovative cell-based protein arrays. We’ll take a deep dive into the Membrane Proteome Array (MPA), a 7,000-protein array platform that tests binding of biotherapeutics across the full human membrane and secreted proteome, expressed in unfixed cells.
Participants will learn how:
- Integral Molecular’s MPA rapidly and accurately identifies potential off-target binding liabilities
- MPA data support both lead selection and IND submissions with advantages over tissue cross-reactivity studies
- Cell-based protein arrays, like the MPA, are rapidly progressing towards FDA endorsement